Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea FDA Withdraws Abbott's Meridia; Criticism Increases On Agency's Dependence On U.S. FDA For Safety

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Korea FDA banned new prescriptions for Abbott's obesity product sibutramine while it recommended "voluntary withdrawal" of the product following similar actions in the U.S. and Europe, drawing criticism that KFDA is too reliant on foreign agencies for monitoring drug safety

You may also be interested in...



In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy

The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications

In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy

The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications

In Replay Of Avandia Ban, Saudi Arabia Is First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy

Country's Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long-acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications.

Related Content

UsernamePublicRestriction

Register

SC073283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;